Lead program STAR-LLD, a continuous low-dose lenalidomide delivery platform, represents a high-potential cross-indication opportunity (MM, CLL, lymphoma and solid cancers) for expansion partnerships or licensing deals with pharma collaborators seeking improved tolerability and duration of therapy.

Delivery platforms Starton's multi modality delivery approach (subcutaneous, oral, transdermal, on-body) enables collaboration with drug developers across existing approved therapies to extend exposure and improve patient adherence, creating inroads for co-development or tech licensing discussions.

Clinical momentum Recent Phase 1b positive data and ongoing engagement at industry events position Starton as a credible partner for advancing dermal and durable-release formulations, presenting opportunities for sponsored development programs or milestone-driven partnerships.

Financial signals External funding activity and a planned public listing indicate readiness for strategic collaborations to scale manufacturing, distribution, and regulatory support, suggesting outreach for co-investment, strategic alliances, or milestone-based financing.

Manufacturing readiness Recent leadership promotions and a collaboration with Bend Bioscience highlight growing in-house and partner manufacturing capabilities, offering potential for scalable manufacturing agreements, tech transfer deals, or CRO/CDMO partnerships to accelerate timelines.